FDA: New Data Show No Stroke Risk With Pfizer Inc. (JOBS) Inhaler
WASHINGTON (Reuters) - Early data from a 4-year clinical trial show no increased risk of stroke in patients given Pfizer Inc's lung drug Spiriva compared with placebo, the U.S. Food and Drug Administration said on Tuesday.